Drug intelligence / Profile preview

DW1032

Development stage: Preclinical
Lead developer: Daewon Pharm
Modality: Small Molecules

Overview

DW1032 is a small molecule compound being developed by Dong-Wha Pharmaceutical for the treatment of pulmonary fibrosis. It acts by modulating fibrosis-related signaling pathways to inhibit the progression of fibrotic disease in the lungs. While the specific molecular target has not been publicly disclosed, the drug is designed to interfere with the signaling cascades that drive myofibroblast activation and extracellular matrix deposition. As of the latest company pipeline reports, DW1032 is in the preclinical stage of development.

Beyond the preview

Go deeper on DW1032.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DW1032.

Explore the full profile